🧬 Biotech Catalyst Calendar

Updated daily · catalystalert.io + dansfera.com Admin
19
Upcoming
0
This Month
19
Trial Readouts
0
PDUFA Dates
0
AdCom Votes
Type: All 🔬 Trial 💊 PDUFA 🏛️ AdCom 📊 Earnings
Mkt Size: All ≥$1B ≥$5B ≥$10B ≥$50B
Date Ticker Company Drug Type Phase PoA Mkt Size Notes
2026-05-25
in 97 days 		AZNCF ASTRAZENECA PLC AZD9550 Trial Phase 2 — $50B Primary completion for AZD6234 trial (NCT06862791) in Obesity or Overweight
2026-07-15
in 287 days 		LXRX LEXICON PHARMACEUTICALS, INC. Sotagliflozin Trial Phase 3 — $55B Primary completion for Sotagliflozin trial (NCT06481891) in Obstructive Cardiomyopathy, Hy
2026-07-15
in 287 days 		GPCR Structure Therapeutics Inc. Aleniglipron Trial Phase 2 — $50B Primary completion for Aleniglipron trial (NCT06693843) in Obesity, Overweight, or Chronic
2026-07-24
in 296 days 		AZN AstraZeneca PLC exenatide Trial Phase 3 — $55B Primary completion for Placebo trial (NCT06151964) in Overweight and Obesity
2026-07-31
in 303 days 		WXI WUXI Semaglutide Trial Phase 3 — $55B Primary completion for Semaglutide trial (NCT07064486) in Type 2 Diabetes (T2DM)
2026-08-06
in 378 days 		AZN AstraZeneca PLC AZD6234 Trial Phase 2 — $50B Primary completion for AZD6234 trial (NCT07017179) in Obesity/Overweight
2026-08-15
in 387 days 		LLY Eli Lilly and Company Semaglutide Trial Phase 3 — $55B Primary completion for Semaglutide trial (NCT06260722) in Diabetes Mellitus, Type 2
2026-10-15
in 587 days 		GPCR Structure Therapeutics Inc. Aleniglipron Trial Phase 2 — $50B Primary completion for Aleniglipron trial (NCT07400588) in Obese
2026-11-15
in 687 days 		MNKD MannKind Corporation Technosphere Insulin Trial Phase 3 — $55B Primary completion for Technosphere Insulin trial (NCT07224321) in Type 1 Diabetes Mellitu
2026-11-23
in 695 days 		NVO Novo Nordisk A/S insulin aspart Trial Phase 3 — $50B Primary completion for Insulin aspart trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-23
in 695 days 		NVO Novo Nordisk A/S insulin glargine Trial Phase 3 — $50B Primary completion for Insulin glargine trial (NCT07076199) in Diabetes Mellitus, Type 1
2026-11-27
in 699 days 		RHHBY Roche Holding AG Semaglutide Trial Phase 2 — $55B Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus
2026-12-15
in 787 days 		LLY Eli Lilly and Company LY3457263 Trial Phase 2 — $55B Primary completion for LY3457263 trial (NCT06897475) in Type 2 Diabetes
2027-01-21
in 9693 days 		AMGN Amgen Inc. Maridebart cafraglutide Trial Phase 3 — $80B Primary completion for Maridebart cafraglutide trial (NCT06858878) in Type 2 Diabetes Mell
2027-01-25
in 9697 days 		PFE PFIZER MET233 and MET097 Trial Phase 2 — $50B Primary completion for MET233 and MET097 trial (NCT06924320) in Obesity and Obesity-relate
2027-02-08
in 9780 days 		RHHBY Roche Holding AG RO7795081 Trial Phase 2 — $50B Primary completion for RO7795081 trial (NCT07112872) in Type 2 Diabetes Mellitus
2027-02-08
in 9780 days 		RHHBY Roche Holding AG Semaglutide Trial Phase 2 — $55B Primary completion for Semaglutide trial (NCT07112872) in Type 2 Diabetes Mellitus
2027-02-26
in 9798 days 		AZN AstraZeneca PLC exenatide Trial Phase 3 — $55B Primary completion for Placebo trial (NCT05138133) in Lupus Nephritis
2027-04-27
in 9999 days 		AMGN Amgen Inc. Maridebart cafraglutide Trial Phase 3 — $80B Primary completion for Maridebart cafraglutide trial (NCT06987695) in Obesity Disease